Biotech | May 16, 2022
Inmagene receives USFDA IND clearance for a third-generation BTK inhibitor
It is developing the drug candidate to potentially treat immunological diseases
It is developing the drug candidate to potentially treat immunological diseases
AbbVie receives the option to license worldwide rights to CUG252 from Cugene, a clinical-stage and potential best-in-class Treg-selective IL-2 mutein, building on AbbVie's commitment to developing novel therapies in immunology
WHO and UNICEF call on governments, industry, donors and civil society to fund and prioritize access to assistive products
Tirzepatide is primarily indicated for the treatment of T2D and is expected to receive its decision from the FDA in Q2 2022
Huntington Medical Research Institutes present first-of-its-kind study examining impact of erectile dysfunction drugs on major adverse cardiovascular events and mortality
In clinical trials, treatment proved more effective than other therapies evaluated
Q1 net sales increased by 12.2% to € 5,198 million compared with the year-earlier quarter
A seasoned professional, he will lead the strategy and business operations of Cadila’s branded prescriptions pharma business
India has the second-largest number of adults with diabetes globally, after China
The pharma companies will bring quality products at competitive prices to consumers in Oman and help bring down the cost of healthcare
Subscribe To Our Newsletter & Stay Updated
